Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.37 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001526 | 0.87 | LMNA (0.39) | LTA4HALDH1A1CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL49789 | 0.78 | ALDH1A1 (0.39) | LTA4HTDP1L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL5830120 | 0.74 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL3183185 | 0.74 | TAAR1 (0.46) | LTA4HCYP1A2TSHRTDP1ALDH1A1 | |
| SCHEMBL6774703 | 0.73 | MMP2 (0.37) | PPARA | |
| SCHEMBL11836140 | 0.73 | LTA4H (0.43) | LTA4HESR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL4942739 | 0.73 | LTA4H (0.43) | LTA4HESR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL28330356 | 0.72 | CHRNA7 (0.66) | LTA4HCYP1A2CYP2C9CYP2C19ESR1 | |
| SCHEMBL11693379 | 0.72 | CHRNA7 (0.66) | LTA4HCYP1A2CYP2C9CYP2C19ESR1 | |
| SCHEMBL17215464 | 0.71 | LTA4H (0.47) | LTA4HCYP1A2CYP2C9CYP2C19ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713146-B2 | SINGLY RECORDABLE COMPACT DISC (CD-R) | BAYER AKTIENGESELLSCHAFT (DE) | 2004-03-30 | — | — | US | claimed |
| EP-1322906-A1 | OPTICAL DATA STORAGE DEVICE CONTAINING A CO-PHTHALOCYANIN COMPLEX IN THE OPTICALLY WRITABLE INFORMATION LAYER | Bayer Aktiengesellschaft (DE) | 2003-07-02 | — | — | EP | claimed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020127366-A1 | Optical data stores containing a Co-phthalocyanine complex in the information layer recordable using light | LANXESS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | claimed |
| WO-2002025205-A1 | OPTICAL DATA STORAGE DEVICE CONTAINING A CO-PHTHALOCYANIN COMPLEX IN THE OPTICALLY WRITABLE INFORMATION LAYER | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | claimed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001087851-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| EP-2526138-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| EP-3981819-B1 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | SIRIGEN II LTD (GB) | 2024-02-28 | — | — | EP | disclosed |
| EP-4322238-A2 | NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION | Sirigen II Limited (GB) | 2024-02-14 | — | — | EP | disclosed |
| US-11899018-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-11874278-B2 | Reagents for directed biomarker signal amplification | SIRIGEN II LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-0661350-B1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON CATALYTIC CHEM IND (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-5817843-A | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| US-5608091-A | SHEETS FOR HEAT EXCHANGING AND OPTICAL RECORDING MATERIAL | NIPPON SHOKUBAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0661350-A1 | Quinizarin compound, method for production thereof, and use therefor | NIPPON SHOKUBAI CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0183191-B1 | THIENYLTHIAZOLE COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-05-10 | — | — | EP | disclosed |
| US-4720493-A | Thienylthiazole compounds | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1988-01-19 | — | — | US | disclosed |
| EP-0183191-A1 | Thienylthiazole compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11874278-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | LTA4H 2158/4885CYP1A2 4879/4885CYP2C9 4865/4885 |
| US-20230273215-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | LTA4H 2260/4885CYP1A2 4883/4885CYP2C9 4878/4885 |
| US-11899018-B2 | Reagents for directed biomarker signal amplification | RNGTT, CAPG, CA14 | LTA4H 2158/4885CYP1A2 4879/4885CYP2C9 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.